Experimental Hematology
Volume 35, Issue 5 , Pages 712-723 , May 2007

DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation

  • Olaf Hopfer

      Affiliations

    • Department of Hematology, Oncology and Transfusion Medicine, Charité, Campus Benjamin Franklin, Berlin, Germany
    • ,
  • Martina Komor

      Affiliations

    • Department of Hematology and Oncology, Hospital of J.W. Goethe University, Frankfurt/Main, Germany
    • ,
  • Ina Sabine Koehler

      Affiliations

    • Department of Hematology, Oncology and Transfusion Medicine, Charité, Campus Benjamin Franklin, Berlin, Germany
    • ,
  • Matthias Schulze

      Affiliations

    • German Institute of Human Nutrition (DIFE) Potsdam-Rehbruecke, Nuthetal, Germany
    • ,
  • Dieter Hoelzer

      Affiliations

    • Department of Hematology and Oncology, Hospital of J.W. Goethe University, Frankfurt/Main, Germany
    • ,
  • Eckhard Thiel

      Affiliations

    • Department of Hematology, Oncology and Transfusion Medicine, Charité, Campus Benjamin Franklin, Berlin, Germany
    • ,
  • Wolf-Karsten Hofmann

      Affiliations

    • Department of Hematology, Oncology and Transfusion Medicine, Charité, Campus Benjamin Franklin, Berlin, Germany
    • Corresponding Author InformationOffprint requests to: Wolf-K. Hofmann, M.D., Ph.D., Department of Hematology, Oncology and Transfusion Medicine, Charité University Hospital, Campus Benjamin Franklin, 12203 Berlin, Germany

Received 19 July 2006 ,Revised 10 January 2007 ,Accepted 16 January 2007.

References 

  1. Hofmann WK, Koeffler HP. Myelodysplastic syndrome. Annu Rev Med. 2005;56:1–16
  2. Kitagawa M, Saito I, Kuwata T, et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia. 1997;11:2049–2054
  3. Hofmann WK, Kalina U, Wagner S, et al. Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes. Exp Hematol. 1999;27:395–400
  4. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415–428
  5. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet. 1991;48:880–888
  6. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199
  7. Uchida T, Kinoshita T, Nagai H, et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood. 1997;90:1403–1409
  8. Quesnel B, Guillerm G, Vereecque R, et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998;91:2985–2990
  9. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood. 2002;100:2957–2964
  10. Toyota M, Ahuja N, Suzuki H, et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 1999;59:5438–5442
  11. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP. Methylation profiling in acute myeloid leukemia. Blood. 2001;97:2823–2829
  12. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific pcr: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821–9826
  13. Hofmann WK, Tsukasaki K, Takeuchi N, Takeuchi S, Koeffler HP. Methylation analysis of cell cycle control genes in adult T-cell leukemia/lymphoma. Leuk Lymphoma. 2001;42:1107–1109
  14. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood. 2004;104:2492–2498
  15. Corn PG, Kuerbitz SJ, van Noesel MM, et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res. 1999;59:3352–3356
  16. Kato N, Fujimoto H, Yoda A, et al. Regulation of Chk2 gene expression in lymphoid malignancies: involvement of epigenetic mechanisms in Hodgkin's lymphoma cell lines. Cell Death Differ. 2004;11:S153–S161
  17. Uehara E, Takeuchi S, Tasaka T, et al. Aberrant methylation in promoter-associated CpG islands of multiple genes in therapy-related leukemia. Int J Oncol. 2003;23:693–696
  18. Yu J, Zhang H, Gu J, et al. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer. 2004;4:65
  19. Esteller M. Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin Immunol. 2003;109:80–88
  20. Esteller M, Guo M, Moreno V, et al. Hypermethylation-associated inactivation of the cellular retinol-binding-protein 1 gene in human cancer. Cancer Res. 2002;62:5902–5905
  21. Hofmann WK, de Vos S, Komor M, Hoelzer D, Wachsman W, Koeffler HP. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood. 2002;100:3553–3560
  22. Komor M, Guller S, Baldus CD, et al. Transcriptional profiling of human hematopoiesis during in vitro lineage-specific differentiation. Stem Cells. 2005;23:1154–1169
  23. Brazma A, Hingamp P, Quackenbush J, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001;29:365–371
  24. Esteller M, Tortola S, Toyota M, et al. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res. 2000;60:129–133
  25. House MG, Guo M, Iacobuzio-Donahue C, Herman JG. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis. 2003;24:193–198
  26. Wong IH, Ng MH, Huang DP, Lee JC. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood. 2000;95:1942–1949
  27. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998;95:6870–6875
  28. Katzenellenbogen RA, Baylin SB, Herman JG. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood. 1999;93:4347–4353
  29. Tort F, Hernandez S, Bea S, et al. CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. Blood. 2002;100:4602–4608
  30. Yu J, Zhang HY, Ma ZZ, Lu W, Wang YF, Zhu JD. Methylation profiling of twenty-four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res. 2003;13:319–333
  31. Tohyama K, Tohyama Y, Nakayama T, Ueda T, Nakamura T, Yoshida Y. A novel factor-dependent human myelodysplastic cell line, MDS92, contains haemopoietic cells of several lineages. Br J Haematol. 1995;91:795–799
  32. Bruno L, Hoffmann R, McBlane F, et al. Molecular signatures of self-renewal, differentiation, and lineage choice in multipotential hemopoietic progenitor cells in vitro. Mol Cell Biol. 2004;24:741–756
  33. Hardie LJ, Darnton SJ, Wallis YL, et al. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett. 2005;217:221–230
  34. Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia. 1999;13:393–399
  35. Svensson E, Eriksson H, Gekas C, Olofsson T, Richter J, Gullberg U. DNA-binding dependent and independent functions of WT1 protein during human hematopoiesis. Exp Cell Res. 2005;308:211–221
  36. Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J. 2001;20:1897–1909
  37. Werner H, Re GG, Drummond IA, et al. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci U S A. 1993;90:5828–5832
  38. Zhang P, Wang J, Gao W, Yuan BZ, Rogers J, Reed E. CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer. Mol Cancer. 2004;3:14
  39. Lukas C, Falck J, Bartkova J, Bartek J, Lukas J. Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat Cell Biol. 2003;5:255–260
  40. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432:316–323
  41. Lee SB, Kim SH, Bell DW, et al. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni syndrome. Cancer Res. 2001;61:8062–8067
  42. Craig AL, Hupp TR. The regulation of CHK2 in human cancer. Oncogene. 2004;23:8411–8418
  43. Hofmann WK, Miller CW, Tsukasaki K, et al. Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias. Leuk Res. 2001;25:333–338
  44. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864–870
  45. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–921
  46. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22:8581–8589
  47. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580–584
  48. Fukuda S, Pelus LM. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood. 2001;98:2091–2100
  49. Badran A, Yoshida A, Wano Y, et al. Expression of the anti-apoptotic gene survivin in myelodysplastic syndrome. Int J Oncol. 2003;22:59–64
  50. Invernizzi R, Travaglino E, Lunghi M, et al. Survivin expression in acute leukemias and myelodysplastic syndromes. Leuk Lymphoma. 2004;45:2229–2237
  51. Yamamoto K, Abe S, Nakagawa Y, et al. Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia. Leuk Res. 2004;28:1203–1211
  52. Gurbuxani S, Xu Y, Keerthivasan G, Wickrema A, Crispino JD. Differential requirements for survivin in hematopoietic cell development. Proc Natl Acad Sci U S A. 2005;102:11480–11485

PII: S0301-472X(07)00112-9

doi: 10.1016/j.exphem.2007.01.054

Experimental Hematology
Volume 35, Issue 5 , Pages 712-723 , May 2007

Article Tools

* Image Usage & Resolution